Measuring dose-related efficacy of eptinezumab for migraine prevention: Post hoc analysis of PROMISE-1 and PROMISE-2

被引：0
|
作者：
Apelian, R. G. [1 ]
Boyle, L. [2 ]
Hirman, J. [3 ]
Asher, D. [4 ]
机构：
[1] Huntington Headache & Neurol, Arcadia, CA USA
[2] Lundbeck LLC, Deerfield, IL USA
[3] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA
[4] Lundbeck LLC, Deerfield, IL USA
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-181
引用
收藏
页码：151 / 152
页数：2
相关论文
共 50 条
  • [31] Eptinezumab for Prevention of Chronic Migraine (CM): Results of 2 Quarterly Intravenous Infusions in the Phase 3 PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and efficacy-2) Trial
    Lipton, R. B.
    Goadsby, P. J.
    Azimova, J.
    Ashina, M.
    Spierings, E. L. H.
    Winner, P. K.
    Schaeffler, B.
    Biondi, D.
    Bhattacharya, S.
    Smith, J.
    Cady, R.
    HEADACHE, 2018, 58 (08): : 1300 - 1300
  • [32] A Phase 3 Study to Evaluate Eptinezumab for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) Trial
    Lipton, R. B.
    Saper, J.
    Ashina, M.
    Biondi, D.
    Bhattacharya, S.
    Hirman, J.
    Schaeffler, B.
    Cady, R.
    HEADACHE, 2018, 58 : 80 - 80
  • [33] Change in Migraine Diagnosis After Preventive Treatment With Eptinezumab: Post Hoc Analysis of the PROMISE Studies
    Pozo-Rosich, P.
    Dodick, D.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [34] Change in Migraine Diagnosis After Preventive Treatment with Eptinezumab: Post Hoc Analysis of the PROMISE Studies
    Cady, Roger
    Pozo-Rosich, Patricia
    Dodick, David
    Ettrup, Anders
    Hirman, Joe
    Asher, Divya
    ANNALS OF NEUROLOGY, 2022, 92 : S40 - S40
  • [35] Change in migraine diagnosis after preventive treatment with eptinezumab: Post hoc analysis of the PROMISE studies
    Pozo-Rosich, P.
    Dodick, D. W.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    HEADACHE, 2022, 62 : 134 - 134
  • [36] Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2
    Diener, Hans-Christoph
    Marmura, Michael J.
    Tepper, Stewart J.
    Cowan, Robert
    Starling, Amaal J.
    Diamond, Merle L.
    Hirman, Joe
    Mehta, Lahar
    Brevig, Thomas
    Sperling, Bjorn
    Cady, Roger
    HEADACHE, 2021, 61 (01): : 125 - 136
  • [37] Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
    Stephen Silberstein
    Merle Diamond
    Nada A. Hindiyeh
    David M. Biondi
    Roger Cady
    Joe Hirman
    Brent Allan
    Susan Pederson
    Barbara Schaeffler
    Jeff Smith
    The Journal of Headache and Pain, 2020, 21
  • [38] Eptinezumab Reduced the Frequency of Migraine Days in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
    Diener, H. -C.
    Marmura, M.
    Hirman, J.
    Mehta, L.
    Brevig, T.
    Brunner, E.
    Cady, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 155 - 155
  • [39] Eptinezumab Reduced the Frequency of Migraine Days in Patients With Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
    Diener, H.
    Marmura, M.
    Hirman, J.
    Mehta, L.
    Brevig, T.
    Brunner, E.
    Cady, R.
    HEADACHE, 2020, 60 : 107 - 107
  • [40] Efficacy and Safety of Eptinezumab in Patients With Chronic Migraine PROMISE-2 (vol 94, pg e1365, 2020)
    Lipton
    NEUROLOGY, 2023, 101 (06)
12345